BOSTON, Mass. (July 26, 2009) — Crack open the latest medical textbook to the chapter on type 2, or adult-onset, diabetes, and you’ll be hard pressed to find the term “immunology” anywhere. This is because metabolic conditions and immunologic conditions are, with a few exceptions, distant cousins.
However, a group of papers appearing in Nature Medicine, two of which are from Harvard Medical School researchers, have linked type 2 diabetes with immunology in a way that might persuade leading researchers to start viewing them as siblings.
In the first study, researchers used two common over-the-counter allergy medications to reduce both obesity and type 2 diabetes in mice. The medications, called Zaditor and cromolyn, stabilize a population of inflammatory immune cells called mast cells. In the second study, researchers found that a kind of white blood cell called a regulatory T cell, once thought to manage only other white blood cells, also acts as a liaison between the metabolic and immune systems — in this case, controlling inflammation in fat tissue. Fat tissue from obese and insulin-resistant mice and people is marked by a dramatic absence of this cell type, in dramatic contrast to an already reported overabundance in fat tissue of inflammatory immune cells called macrophages.
“It seems that we’re seeing the emergence of a new biomedical discipline: immunometabolism,” says HMS professor of pathology Diane Mathis, senior author on one of the papers.
Both papers will appear online July 26 in Nature Medicine.
Type 1 and type 2 diabetes both involve abnormalities in the insulin-producing beta cells of the pancreas, but their root causes are completely different. Type 1 diabetes is an autoimmune disease in which the immune system attacks the pancreas, destroying its ability to produce insulin. In contrast, type 2 diabetes is a strictly metabolic condition in which cells grow increasingly deaf to insulin signals and thus lose their ability to metabolize glucose. In both cases, glucose mounts in the blood, at times to fatal levels.
But it is becoming increasingly clear that we should also think of type 2 diabetes in the context of immune function, Harvard scientists assert.
Guo-Ping Shi, Biochemist from the Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, began to suspect such a connection when, in a previous study, he found mast cells present in a variety of inflammatory vascular diseases.
Mast cells are immune cells that facilitate healing in wounded tissue, primarily by increasing blood flow to the site. However, in certain conditions mast cells build up to levels far beyond what the body needs. As a result these cells become unstable and eventually, like punctured trash bags, leak molecular “garbage” into the tissue. This can result in chronic inflammation that causes asthma and certain allergies.
As Shi and postdoctoral research fellow Jian Liu discovered, mast cells were far more abundant in fat tissue from obese and diabetic humans and mice than they were in normal weight fat tissue. This led to an obvious question: by regulating mast cells, could we then control the symptoms?
To find out, Shi and colleagues took a group of obese and diabetic mice and, for a period of two months, treated them with either ketotifen fumarate (also called Zaditor) or cromolyn, both over-the-counter allergy drugs.
“We knew from published research that both cromolyn and Zaditor help stabilize mast cells in people suffering from allergy or asthma,” said Shi. “It’s almost as if the drugs place an extra layer of plastic on the ripped trash bag. So it seemed like a logical place to begin.”
The mice were divided into four groups. The first was the control group; the second group was simply switched to a healthy diet; the third was given cromolyn or ketotifen fumarate; and the fourth was both given the drug and switched to a healthy diet.
While symptoms of the second group improved moderately, the third group demonstrated dramatic improvements in both body weight and diabetes. The fourth group exhibited nearly 100 percent recovery in all areas.
To bolster these findings, Shi and colleagues then took a group of mice whose ability to produce mast cells was genetically impaired. Despite three months of a diet rich in sugar and fat, these mice neither became obese nor developed diabetes.
“The best thing about these drugs is that we know it’s safe for people,” says Shi. “The remaining question now is: Will this also work for people?”
Shi now intends to test both cromolyn and ketotifen fumarate on obese and diabetic non-human primates.
Beyond friendly fire
In findings independent of Shi, researchers at Harvard Medical School and Joslin Diabetes Center discovered that a class of immune system cells called regulatory T cells, or Tregs, were abundant in the abdominal fat tissue of normal-weight humans and mice, but were virtually absent in the same tissue from obese and diabetic humans and mice.
Their numbers were inversely correlated with the numbers of a class of inflammatory immune cells, macrophages, in a sense creating parallel universes of fat. While obese and diabetic fat tissue was full of inflammatory macrophages and nearly absent of Tregs, normal-weight fat tissue was the diametric opposite.
“For immunologists this is very important, because Tregs had always been thought to control other T cells and that’s it,” says Markus Feuerer, a postdoctoral researcher in the lab of HMS professors of pathology Diane Mathis and Christophe Benoist. “But this is an entirely new concept.” Mathis and Benoist collaborated on the study with Steven Shoelson, HMS professor of medicine at the Joslin Diabetes Center.
“I come at this studying the effects of obesity and why it can spread systemically to cause chronic health problems,” says Shoelson, an endocrinologist. “It’s possible that the inflammation caused by macrophages results in insulin resistance. And it’s more likely, from what we’ve just seen, that Tregs are keeping the macrophages in check in normal fat tissue, thus preventing inflammation.”
For over a decade, Tregs have been known as guardians for the immune system, ensuring that when white blood cells attack a foreign pathogen they don’t become overzealous and harm healthy host tissue in a kind of friendly fire. Malfunctioning Tregs, however, have recently been implicated in diseases as diverse as multiple sclerosis and certain cancers.
“Now we’re seeing that Tregs may be needed to prevent metabolic abnormalities as well,” says Mathis. She adds, half joking, “As an immunologist, I always thought that type 2 diabetes was a pretty boring condition. After these findings, I’m starting to change my mind.”
Both studies were funded by the National Institutes of Health.
Written by David Cameron
Nature Medicine, July 26, 2009, early online publication
“Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice”
Jian Liu1, Adeline Divoux2, Jiusong Sun1, Jie Zhang1, Karine Clément2-4, Jonathan N Glickman1, Galina K Sukhova1, Paul J Wolters5, Juan Du1, Cem Z Gorgun6, Alessandro Doria7, Peter Libby1, Richard S Blumberg1, Q1 Barbara B Kahn8, Gokhan S Hotamisligil6 & Guo-Ping Shi1
1-Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
2-Institut National de la Sante´ et de la Recherche Me´dicale, U872, Nutriomique, Paris, France.
3-University Pierre and Marie Curie-Paris 6, Cordeliers Research Center, Paris, France. 4-Assistance Publique-Ho?pitaux de Paris, Nutrition Department, Pitie´-Salpetrie`re Hospital, Paris, France.
5-Department of Medicine, University of California, San Francisco, California
6-Department of Genetics and Complex Diseases, School of Public Health, Harvard University, Boston, Massachusetts
7-Section on Genetics and Epidemiology, Joslin Diabetes Center and Harvard Medical School, Boston, Massachusetts.
8-Department of Medicine, Beth Israel-Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
“Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters”
Markus Feuerer1,5, Laura Herrero2,5, Daniela Cipolletta1,4,5, Afia Naaz2, Jamie Wong1,5, Ali Nayer2, Jongsoon Lee2, Q1 Allison Goldfine3, Christophe Benoist1,5, Steven Shoelson2 & Diane Mathis1,5
1-Immunology and Immunogenetics, 2-Cellular and Molecular Physiology and 3-Clinical Research, Joslin Diabetes Center, Department of Medicine, Brigham and Women’s
Hospital, Harvard Medical School, Boston, Massachusetts
4-European School of Molecular Medicine, Naples, Italy.
5-Department of Pathology, Harvard Medical School, Boston, Massachusetts, Department of Biochemistry and Molecular Biology, School of Pharmacy, University
of Barcelona, Barcelona, Spain; Alnylam Pharmaceuticals, Cambridge, Massachusetts
Harvard Medical School http://hms.harvard.edu has more than 7,500 full-time faculty working in 11 academic departments located at the School’s Boston campus or in one of 47 hospital-based clinical departments at 17 Harvard-affiliated teaching hospitals and research institutes. Those affiliates include Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Cambridge Health Alliance, Children’s Hospital Boston, Dana-Farber Cancer Institute, Forsyth Institute, Harvard Pilgrim Health Care, Hebrew SeniorLife, Joslin Diabetes Center, Judge Baker Children’s Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Mount Auburn Hospital, Schepens Eye Research Institute, Spaulding Rehabilitation Hospital, and VA Boston Healthcare System.
Brigham and Women’s Hospital http://www.brighamandwomens.org/ is dedicated to serving the needs of the community. It is committed to providing the highest quality health care to patients and their families, to expanding the boundaries of medicine through research, and to educating the next generation of health care professionals.